Supply of cephazolin (as sodium) (DBL CEPHAZOLIN SODIUM) products by Hospira Australia Pty Ltd

Overview

The Therapeutic Goods Act 1989 was enacted to regulate the quality, efficacy, and safety of therapeutic goods supplied in Australia, aiming to protect public health by ensuring that only therapeutic goods of acceptable quality are available for use. The Act provides a framework for the regulation of therapeutic goods, including medicines, medical devices, and blood and blood components, through the Therapeutic Goods Administration (TGA). The Act was introduced to address the need for a comprehensive regulatory system that ensures the safety and quality of therapeutic goods available to the public. The consent granted under section 14 and 14A of the Act, as published in the Gazette on April 15, 2013, allows for the supply of specific products by Hospira Australia Pty Ltd, despite non-conformance with certain address details, subject to specific conditions until August 1, 2013. This measure underscores the TGA’s commitment to maintaining rigorous standards while facilitating the timely availability of essential therapeutic goods.

Scope and Application

The Therapeutic Goods Act 1989 governs the regulation of therapeutic goods in Australia, and its scope extends to ensuring that these goods meet safety, quality, and efficacy standards. Specifically, section 14 and 14A of the Act pertain to the supply of therapeutic goods, and the notice dated April 15, 2013, by the delegate of the Secretary of the Department of Health and Ageing pertains to the temporary supply of certain pharmaceutical products by Hospira Australia Pty Ltd. This consent is applicable to the supply of cephazolin (as sodium) and cefotaxime (as sodium) products that do not conform to the current sponsor's address details as stipulated in Therapeutic Goods Order (TGO) 69. The consent is conditional and limited in scope, applying only to the specified products supplied by Hospira Australia Pty Ltd and is valid until August 1, 2013. The consent is also subject to the condition that no changes other than the address details have been made to the products, and arrangements are in place for customer queries or complaints to be forwarded to the new address.

Key Provisions

The Therapeutic Goods Act 1989, specifically section 14 and 14A, outlines provisions for the supply of therapeutic goods that do not conform to specified standards. In this instance, the delegate of the Secretary of the Department of Health and Ageing has provided consent for Hospira Australia Pty Ltd to supply two products: cephazolin (as sodium) and cefotaxime (as sodium). These products, which are intended for injection, are supplied in non-conforming labels, as they still list the previous sponsor address instead of the current one, contrary to the requirements of Therapeutic Goods Order (TGO) 69, paragraph 3(2)(l). This consent is subject to certain conditions, as stipulated in subsection 15(1) of the Act. Under the terms of the consent, the supply of these products by Hospira Australia Pty Ltd is permitted only until August 1, 2013. Furthermore, the consent applies to the currently used labels of the products, which inaccurately list the old Mulgrave address instead of the current Collins Street address. It is explicitly stated that no other changes have been made to the products themselves, maintaining their integrity and purpose as therapeutic goods. Additionally, there must be arrangements in place to ensure that all customer queries or complaints are promptly referred from the old address to the new one, ensuring continued communication and customer service. In terms of obligations, Hospira Australia Pty Ltd is required to adhere to the specified conditions under which the consent was granted. This includes the timely transition of customer inquiries and complaints to the new address, ensuring that the sponsor's address details are corrected as soon as possible and no later than August 1, 2013. The company must also ensure that the products supplied are not altered in any way other than the label correction, maintaining their therapeutic efficacy and safety. Failure to comply with these obligations could result in serious repercussions. Failure to comply with the conditions of the consent, or with the broader requirements of the Therapeutic Goods Act 1989 and TGO 69, may result in significant legal consequences. Although specific offences, penalties, or civil/criminal consequences are not detailed in the provided text, breaches of the Act or the orders made under it can typically lead to penalties. In general, such breaches could result in fines, corrective actions, product recalls, or even criminal charges, depending on the severity and intent of the breach. The Therapeutic Goods Act is designed to protect public health and safety, and any non-compliance is taken seriously by regulatory authorities.